Potential prognostic biomarkers of hepatocellular carcinoma based on 4D label-free quantitative proteomics analysis pilot investigation.

IF 2.3 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

International Journal of Biological Markers Pub Date : 2024-03-01 Epub Date: 2023-11-13 DOI:10.1177/03936155231212925

Lida Suo, Xiangnan Liang, Weibin Zhang, Mingwei Gao, Taiheng Ma, Daosheng Hu, Yilin Song, Zhenming Gao

{"title":"Potential prognostic biomarkers of hepatocellular carcinoma based on 4D label-free quantitative proteomics analysis pilot investigation.","authors":"Lida Suo, Xiangnan Liang, Weibin Zhang, Mingwei Gao, Taiheng Ma, Daosheng Hu, Yilin Song, Zhenming Gao","doi":"10.1177/03936155231212925","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma carries a poor prognosis and poses a serious threat to global health. Currently, there are few potential prognostic biomarkers available for the prognosis of hepatocellular carcinoma.Methods: This pilot study used 4D label-free quantitative proteomics to compare the proteomes of hepatocellular carcinoma and adjacent non-tumor tissue. A total of 66,075 peptides, 6363 identified proteins, and 772 differentially expressed proteins were identified in specimens from three hepatocellular carcinoma patients. Through functional enrichment analysis of differentially expressed proteins by Gene Ontology, KEGG pathway, and protein domain, we identified proteins with similar functions.Results: Twelve differentially expressed proteins (RPL17, RPL27, RPL27A, RPS5, RPS16, RSL1D1, DDX18, RRP12, TARS2, YARS2, MARS2, and NARS1) were selected for identification and validation by parallel reaction monitoring. Subsequent Western blotting confirmed overexpression of RPL27, RPS16, and TARS2 in hepatocellular carcinoma compared to non-tumor tissue in 16 pairs of clinical samples. Analysis of The Cancer Genome Atlas datasets associated the increased expression of these proteins with poor prognosis. Tissue microarray revealed a negative association between high expression of RPL27 and TARS2 and the prognosis of hepatocellular carcinoma patients, although RPS16 was not significant.Conclusions: These data suggest that RPL27 and TARS2 play an important role in hepatocellular carcinoma progression and may be potential prognostic biomarkers of overall survival in hepatocellular carcinoma patients.","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155231212925","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocellular carcinoma carries a poor prognosis and poses a serious threat to global health. Currently, there are few potential prognostic biomarkers available for the prognosis of hepatocellular carcinoma.

Methods: This pilot study used 4D label-free quantitative proteomics to compare the proteomes of hepatocellular carcinoma and adjacent non-tumor tissue. A total of 66,075 peptides, 6363 identified proteins, and 772 differentially expressed proteins were identified in specimens from three hepatocellular carcinoma patients. Through functional enrichment analysis of differentially expressed proteins by Gene Ontology, KEGG pathway, and protein domain, we identified proteins with similar functions.

Results: Twelve differentially expressed proteins (RPL17, RPL27, RPL27A, RPS5, RPS16, RSL1D1, DDX18, RRP12, TARS2, YARS2, MARS2, and NARS1) were selected for identification and validation by parallel reaction monitoring. Subsequent Western blotting confirmed overexpression of RPL27, RPS16, and TARS2 in hepatocellular carcinoma compared to non-tumor tissue in 16 pairs of clinical samples. Analysis of The Cancer Genome Atlas datasets associated the increased expression of these proteins with poor prognosis. Tissue microarray revealed a negative association between high expression of RPL27 and TARS2 and the prognosis of hepatocellular carcinoma patients, although RPS16 was not significant.

Conclusions: These data suggest that RPL27 and TARS2 play an important role in hepatocellular carcinoma progression and may be potential prognostic biomarkers of overall survival in hepatocellular carcinoma patients.

查看原文本刊更多论文

基于4D无标记定量蛋白质组学分析的肝细胞癌潜在预后生物标志物初步研究。

背景:肝细胞癌预后不良，对全球健康构成严重威胁。目前，很少有潜在的生物标志物可用于肝细胞癌的预后。方法:采用4D无标记定量蛋白质组学方法比较肝细胞癌与癌旁非肿瘤组织的蛋白质组学。在3例肝细胞癌患者的标本中共鉴定出66,075个多肽、6363个鉴定蛋白和772个差异表达蛋白。通过基因本体、KEGG通路和蛋白结构域对差异表达蛋白进行功能富集分析，鉴定出功能相似的蛋白。结果:选择12个差异表达蛋白(RPL17、RPL27、RPL27A、RPS5、RPS16、RSL1D1、DDX18、RRP12、TARS2、YARS2、MARS2、NARS1)进行平行反应监测鉴定和验证。随后的Western blotting证实，在16对临床样本中，与非肿瘤组织相比，RPL27、RPS16和TARS2在肝细胞癌中过表达。对癌症基因组图谱数据集的分析表明，这些蛋白的表达增加与预后不良有关。组织芯片显示，RPL27和TARS2的高表达与肝细胞癌患者的预后呈负相关，而RPS16的高表达与肝细胞癌患者的预后无显著相关性。结论:这些数据表明RPL27和TARS2在肝细胞癌的进展中起重要作用，可能是肝细胞癌患者总生存期的潜在预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Biological Markers 医学-生物工程与应用微生物

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.